Aflibercept-Mrbb: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Aflibercept-Mrbb. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Conjunctival hemorrhage | 30% |
| Cataract | 13% |
| Intraocular pressure increased | 11% |
| Eye pain | 10% |
| Vitreous floaters | 10% |
| Ocular hyperemia | 10% |
| Vitreous detachment | 8% |
| Corneal epithelium defect | 6% |
| Injection site pain | 4% |
| Foreign body sensation in eyes | 4% |
| Lacrimation increased | 4% |
| Vision blurred | 4% |
| Intraocular inflammation | 4% |
| Eyelid edema | 3% |
| Retinal pigment epithelium tear | 2% |
| Injection site hemorrhage | 2% |
| Corneal edema | 1% |
| Retinal detachment | 1% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)
Medical disclaimer: Always consult a qualified healthcare professional about any medication.
Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.
Compare lab testing options near you ↗ (affiliate link)